DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the HESTER BIOSCIENCES LTD (HESTERBIO) share price today?

HESTER BIOSCIENCES LTD (HESTERBIO) is trading at ₹2,447.8 on the NSE, up 0.42% on the day. Source: DocStoX.

What is the PE ratio of HESTER BIOSCIENCES LTD?

HESTER BIOSCIENCES LTD has a price-to-earnings (PE) ratio of 37.4 in the Healthcare sector.

What is the market capitalisation of HESTER BIOSCIENCES LTD?

HESTER BIOSCIENCES LTD has a market capitalisation of approximately ₹2,093 crore.

HESTER BIOSCIENCES LTD

HESTERBIO·NSE·Healthcare

₹2,447.80▲ +10.20 (+0.42%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹2400.00

₹2490.00

52W₹1239

₹266085%

Open

₹2436.90

High

₹2490.00

Low

₹2400.00

Prev Close

₹2437.60

Volume

16.9K

VWAP

₹2433.54

Snapshot

Key fundamentals

Market Cap

₹2,093 Cr

P/E Ratio

37.42Expensive

P/B Ratio

5.12

EPS

₹65.41

Book Value

₹423.00

ROE

15.90%Strong

ROCE

15.00%Decent

Dividend Yield

0.52%

Debt / Equity

0.54Moderate

Face Value

₹10.00

52W High

₹2660.00

52W Low

₹1239.30

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹553

▼ 77.4%downside

Trading at ₹2,448 — 77% above our estimate

BearFair valueBull

₹470₹553₹789

/100

Business quality — Solid

Growth 66Profitability 69Efficiency 18Valuation 52

Plain English

Our view

A steady, established business
Profit growing 27% a year
Fundamental red flags (Piotroski 3/9)

Strengths

Profit growing 27% a year
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

16% ROE fading to 13% over ~10 yrs, on ₹423 book

₹487

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹789

Analyst target

No analyst coverage

—

Blended fair value₹553

What the numbers say

Investment thesis

Bull case

Profit growing 27% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

37.4Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

15.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.54Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹2,093 Cr

P/B

5.12

EPS

₹65.41

Div Yield

0.52%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 37.4×

Growth

Steady

+8% rev CAGR

Profitability

Healthy

15.9% ROE

Financial health

Comfortable

D/E 0.54

Momentum

N/A

No technicals

Today

Trading activity

Delivery %51.5%

Turnover₹411.46L Cr

Trades2,023

VWAP₹2433.54

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.8%

+9.3%

10Y

+12.7%

Profit

+26.7%

+10.3%

10Y

+11.6%

EPS

+27.9%

+10.1%

10Y

+11.2%

Profile

Pros

Company has been maintaining a healthy dividend payout of 21.8%
Company's working capital requirements have reduced from 80.2 days to 54.4 days

Watch-outs

Cons

Stock is trading at 5.01 times its book value
The company has delivered a poor sales growth of 9.19% over past five years.
Company has a low return on equity of 10.8% over last 3 years.
Company might be capitalizing the interest cost

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

54%

Promoter

Promoters

53.7%0.00

Public

46.0%+0.07

FII / FPI

0.3%-0.07

DII

0.0%0.00

Quarterly trend

Ownership over time

Q1 FY27

Promoter53.73%

FII0.31%

Public45.95%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions